劳拉西泮与奥沙西泮治疗酒精性肝病并发酒精戒断综合征患者临床疗效对比研究

doi:10.3969/j.issn.1672-5069.2021.05.026

摘要/Abstract

摘要： 目的对比观察劳拉西泮与奥沙西泮治疗酒精性肝病(ALD)并发酒精戒断综合征(AWS)患者的临床疗效。方法 2017年11月～2020年11月我院诊治的127例ALD并发AWS患者,采用随机数字表法将患者分为对照组63例和观察组64例,分别给予劳拉西泮和奥沙西泮治疗7 d。应用酒精戒断综合征评定量表(AWSS)评估临床症状,应用焦虑自评量表(SAS)评估焦虑症状。采用ELISA法检测血清透明质酸(HA)、层粘连蛋白(LN)、三型前胶原N端肽(PC-Ⅲ)和四型胶原(IV-C)。结果在治疗结束时,观察组有效率为96.9％,显著高于对照组的81.0％,差异有统计学意义(P<0.05);治疗前,两组AWSS和SAS评分和血清ALT、AST、GGT、TBIL、ALP、CHE、HA、LN、PC-Ⅲ和IV-C水平无统计学差异(P>0.05);治疗结束时,观察组AWSS和SAS评分分别为(9.5±2.4)分和(30.8±6.4)分,与对照组【分别为(14.2±3.5)分和(48.2±9.1)分,P<0.05】比,差异显著;血清ALT、AST、GGT、TBIL和ALP水平分别为(30.5±8.1)U/L、(71.6±15.3)U/L、(466.1±22.7)U/L、(23.5±6.5)μmol/L和(82.3±12.4)U/L,显著低于对照组【分别为(52.2±11.3)U/L、(105.6±18.4)U/L、(626.3±25.4)U/L、(35.2±8.6)μmol/L和(118.3±14.7)U/L,P<0.05】;血清HA、PC-Ⅲ和IV-C水平分别为(116.8±18.3)μg/L、(123.1±12.3)μg /L和(80.2±11.6)μg /L,显著低于对照组【分别为(146.2±22.3)μg/L、(155.5±16.8)μg/L和(98.8±15.4)μg/L,P<0.05】。结论奥沙西泮治疗ALD并发AWS患者临床疗效显著,可改善症状,减轻焦虑情绪,促进肝功能恢复。

关键词: 酒精性肝病, 酒精戒断综合征, 劳拉西泮, 奥沙西泮, 治疗

Abstract: Objective This clinical trial aimed to compare the efficacy of lorazepam and oxazepam in treatment of patients with alcoholic liver diseases (ALD) and alcohol withdrawal syndrome (AWS). Methods A total of 127 patients with ALD and AWS were enrolled in our hospital between November 2017 and November 2020, and were randomly divided into control (n=63) and observation group (n=64), receiving lorazepam and oxazepam, respectively, for seven days. The scores of alcohol withdrawal syndrome scale (AWSS) and self-rating anxiety scale (SAS) score were evaluated. Serum hyaluronic acid (HA), laminin (LN), type III procollagen N-terminal peptide (PC-III) and type-IV collagen (IV-C) were detected by ELISA. Results At the end of 7 day treatment, the efficient rate in observation group was 96.9％, significantly higher than 81.0％ in the control (P<0.05); at presentation, the AWSS and SAS, serum alanine transaminase (ALT), aspartate aminotransferase (AST), glutamyl transpeptidase (GGT),total bilirubin (TBIL) and alkaline phosphatase (ALP) as well as HA, LN, PC-Ⅲ and IV-C levels were not significantly different between the two groups(P>0.05); after treatment, the AWSS and SAS in observation were (9.5±2.4) and (30.8±6.4), significantly different as compared to in the control; serum ALT, AST, GGT, TBIL and ALP levels were (30.5±8.1)U/L, (71.6±15.3)U/L, (466.1±22.7)U/L, (23.5±6.5)μmol/L and (82.3±12.4)U/L, all much lower than in the control; serum HA, PC-Ⅲ and IV-C levels were (116.8±18.3)μg/L,(123.1±12.3)μg /L and (80.2±11.6)μg /L, significantly lower than in the control. Conclusion The clinical efficacy of oxazepam is good in treatment of ALD patients with complicated AWS, which could improve clinical symptom and anxiety relieving.

Key words: Alcoholic liver diseases, Alcohol withdrawal syndrome, Lorazepam, Oxazepam, Therapy

刘丽霞, 林应源, 李华敏, 蔡水苗. 劳拉西泮与奥沙西泮治疗酒精性肝病并发酒精戒断综合征患者临床疗效对比研究[J]. 实用肝脏病杂志, 2021, 24(5): 709-712.

Liu Lixia, Lin Yingyuan, Li Huamin, et al. Comparative study on the clinical efficacy of lorazepam and oxazepam in treatment of patients with alcoholic liver diseases and alcohol withdrawal syndrome[J]. Journal of Practical Hepatology, 2021, 24(5): 709-712.

参考文献

[1]孙韬华, 刘振胜, 辛永宁,等. 酒精性肝病治疗研究进展. 实用肝脏病杂志, 2019, 22(2):10-13.
[2]姜浩, 戈宏焱. 熊去氧胆酸联合脂溶性维生素注射液治疗酒精性肝病伴肝内胆汁淤积患者疗效观察. 实用肝脏病杂志, 2017, 20(1):105-106.
[3]Foertsch M J, Winter J B, Rhoades A G, et al.recognition, assessment, and pharmacotherapeutic treatment of alcohol withdrawal syndrome in the intensive care. Crit Care Nurs Q, 2019, 42(1):12-29.
[4]Kong F, Zhang M, Wang H, et al.symptom-triggered alcohol vapor inhalation for postoperative alcohol withdrawal syndrome in patients with gastroesophageal carcinoma. J Buon,2017, 22(5):1266-1271.
[5]Glann J K, Carman M, Thompson J, et al.alcohol withdrawal syndrome: improving recognition and treatment in the emergency department. Adv Emerg Nurs J, 2019, 41(1):65-75.
[6]Hok L, Bozicevic L, Sremec H, et al.Racemization of oxazepam and chiral 1, 4-benzodiazepines:DFT study of the reaction mechanism in aqueous solution. Org Biomol Chem, 2019, 17(6):1471-1479.
[7]王艳, 郝俊, 李军涛,等. 劳拉西泮和奥沙西泮对失眠患者疗效的观察. 世界睡眠医学杂志, 2018, 5(7):775-777.
[8]中华医学会肝病学分会脂肪肝和酒精性肝病学组,中国医师协会脂肪肝专家委员会.酒精性肝病防治指南(2018年更新版).实用肝脏病杂志,2018,21(2): 170-176.
[9]陈彦方,杨德森,姚芳传,等.中国神经病分类与诊断标准(CCDM-3).济南:山东科学技术出版社,2001:79-82.
[10] 缪丽华. 系统化关怀照护模式在乙醇戒断综合征患者中的应用. 解放军护理杂志, 2017, 34(10):48-50.
[11] 夏晓莉, 张烈元, 胡佳俊,等. SAS,SDS评分在肝气郁滞型代谢综合征中医辨证分型中的作用. 中国中西医结合杂志, 2017, 37(7):800-803.
[12] Sinirlioglu Z A, Coskunpinar E, Akbas F, et al. miRNA and mRNA expression profiling in rat brain following alcohol dependence and withdrawal. Cell Mol Biol, 2017, 63(2):49.
[13] Maldonado H, Jose R. novel algorithms for the prophylaxis and management of alcohol withdrawal syndromes–beyond benzodiazepines. Crit Care Clin, 2017, 33(3):559-599.
[14] Salottolo K, Mcguire E, Mains C W, et al. Occurrence, predictors, and prognosis of alcohol withdrawal syndrome and delirium tremens following traumatic injury. Crit Care Med, 2017, 45(5):867-874.
[15] Ferenchak G, Tarenne A . The addition of dexmedetomidine as an adjunctive therapy to benzodiazepine use in alcohol withdrawal syndrome: a literature review. J Addict Nurs, 2017, 28(4):188-195.
[16] Andaluz A, Demoss D, Claassen C, et al. Fixed-dose gabapentin augmentation in the treatment of alcohol withdrawal syndrome: a retrospective, open-label study. Am J Drug Alcohol Abuse, 2019, 46(1):49-57.
[17] Chou J C, Czobor P, Charles O, et al. Acute mania: haloperidol dose and augmentation with lithium or lorazepam. J Clin Psychopharmacol, 2019, 19(6):500-505.
[18] Sundin J, Jutfelt F, Thorlacius M, et al. Behavioural alterations induced by the anxiolytic pollutant oxazepam are reversible after depuration in a freshwater fish. Sci Total Environ, 2019, 665(15):390-399.
[19] Verthein U, Kuhn S, Gabriel K, et al. Treatment of alcohol withdrawal syndrome with oxazepam or clomethiazole - anaturalistic observational study. Psychiatr Prax, 2017, 45(2):95-102.